Literature DB >> 25755746

Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.

Chang Won Jung1, Kang Hee Han1, Hyesil Seol1, Sunhoo Park2, Jae Soo Koh1, Seung-Sook Lee2, Min Joo Kim3, Ik Joon Choi4, Jae Kyung Myung2.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is an undifferentiated tumor of the thyroid that has poor prognosis owing to its aggressive behavior and resistance to current treatments. We hypothesized that the stem cell properties induced by the epithelial-mesenchymal transition (EMT) was one of reasons for the dismal outcome of ATC.
MATERIALS AND METHODS: Paraffin blocks and slides of 17 ATC cases were retrieved. We also collected 60 cases of papillary thyroid carcinoma (PTC) for comparison. We used immunohistochemistry to examine the expression of multiple markers of cancer stem cells and EMT-activating transcriptional factors.
RESULTS: Majority of ATC cases showed loss of epithelial (E)-cadherin expression (15/17); however, all PTC cases (60/60) retained E-cadherin expression. EMT-activating transcription factors, such as snail and slug, were more frequently expressed in ATC than PTC cases (35.3% versus 6.7%, 76.5% versus 5%, respectively). Cancer stem cell markers such as CD133 and nestin were more highly expressed in ATC than PTC (52.9% versus 5%, 52.9% versus 0%, respectively).
CONCLUSION: We found that the expression of EMT-related factors and stem cell markers was higher in ATC than PTC. We therefore conclude that stemness induced by EMT plays an important role in the pathogenesis of ATC.

Entities:  

Keywords:  Epithelial-mesenchymal transition (EMT); anaplastic thyroid carcinoma (ATC); cancer stem cell; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 25755746      PMCID: PMC4348894     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.

Authors:  Guofang Chen; Shuhang Xu; Kostja Renko; Michael Derwahl
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.

Authors:  Sam M Wiseman; Hamid Masoudi; Paddy Niblock; Dmitry Turbin; Ashish Rajput; John Hay; Douglas Filipenko; David Huntsman; Blake Gilks
Journal:  Am J Surg       Date:  2006-05       Impact factor: 2.565

5.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

6.  TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype.

Authors:  Paolo Salerno; Ginesa Garcia-Rostan; Sara Piccinin; Tammaro Claudio Bencivenga; Gennaro Di Maro; Claudio Doglioni; Fulvio Basolo; Roberta Maestro; Alfredo Fusco; Massimo Santoro; Giuliana Salvatore
Journal:  J Clin Endocrinol Metab       Date:  2011-03-09       Impact factor: 5.958

7.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

Review 8.  New therapeutic options for advanced forms of thyroid cancer.

Authors:  Victor Bernet; Robert Smallridge
Journal:  Expert Opin Emerg Drugs       Date:  2014-03-03       Impact factor: 4.191

9.  Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancers (Basel)       Date:  2011-02-21       Impact factor: 6.639

10.  In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.

Authors:  Giovanni Zito; Pierina Richiusa; Alessandra Bommarito; Elvira Carissimi; Leonardo Russo; Antonina Coppola; Monica Zerilli; Vito Rodolico; Angela Criscimanna; Marco Amato; Giuseppe Pizzolanti; Aldo Galluzzo; Carla Giordano
Journal:  PLoS One       Date:  2008-10-28       Impact factor: 3.240

View more
  21 in total

1.  BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma - challenging the roles of Snail and E-Cadherin?

Authors:  Brendon Mitchell; Dominick Leone; Shi Yang; Ashraf Khan; Meera Mahalingam; Jagdish Dhingra
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

2.  Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.

Authors:  Zhilan Li; Xiudi Jiang; Peihong Chen; Xuebing Wu; Aihua Duan; Yiyu Qin
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

Review 3.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

4.  Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.

Authors:  Myriem Boufraqech; Lisa Zhang; Naris Nilubol; Samira M Sadowski; Shweta Kotian; Martha Quezado; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2016-03-30       Impact factor: 12.531

Review 5.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

Review 6.  Tumor-Associated Mast Cells in Thyroid Cancer.

Authors:  Carla Visciano; Nella Prevete; Federica Liotti; Gianni Marone
Journal:  Int J Endocrinol       Date:  2015-08-26       Impact factor: 3.257

7.  The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma.

Authors:  Hyeon Jin Kim; Min-Jung Kim; Areumnuri Kim; Chang Won Jung; Sunhoo Park; Jae Soo Koh; Jae Kyung Myung
Journal:  Cancer Res Treat       Date:  2016-09-01       Impact factor: 4.679

8.  Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.

Authors:  Weixin Liang; Yongqiang Lai; Mingzhang Zhu; Shangshu Huang; Weizhao Feng; Xiaoyu Gu
Journal:  Med Sci Monit       Date:  2016-12-14

9.  Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer.

Authors:  James P De Andrade; Allison W Lorenzen; Vincent T Wu; Maria V Bogachek; Jung M Park; Vivian W Gu; Claire M Sevenich; Victoria C Cassady; Anna C Beck; Mikhail V Kulak; Robert A Robinson; Geeta Lal; Ronald J Weigel
Journal:  Oncotarget       Date:  2017-10-23

Review 10.  Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition.

Authors:  Kemal Behzatoglu
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.